131 related articles for article (PubMed ID: 3621455)
1. Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide.
Pflüger KH; Schmidt L; Merkel M; Jungclas H; Havemann K
Cancer Chemother Pharmacol; 1987; 20(1):59-66. PubMed ID: 3621455
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions.
Pflüger KH; Hahn M; Holz JB; Schmidt L; Köhl P; Fritsch HW; Jungclas H; Havemann K
Cancer Chemother Pharmacol; 1993; 31(5):350-6. PubMed ID: 8431968
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors.
Sinkule JA; Hutson P; Hayes FA; Etcubanas E; Evans W
Cancer Res; 1984 Jul; 44(7):3109-13. PubMed ID: 6539169
[TBL] [Abstract][Full Text] [Related]
4. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of high-dose etoposide after short-term infusion.
Köhl P; Köppler H; Schmidt L; Fritsch HW; Holz J; Pflüger KH; Jungclas H
Cancer Chemother Pharmacol; 1992; 29(4):316-20. PubMed ID: 1537079
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors.
Kreis W; Budman DR; Vinciguerra V; Hock K; Baer J; Ingram R; Schacter LP; Fields SZ
Cancer Chemother Pharmacol; 1996; 38(4):378-84. PubMed ID: 8674162
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer.
Evans WE; Sinkule JA; Crom WR; Dow L; Look AT; Rivera G
Cancer Chemother Pharmacol; 1982; 7(2-3):147-50. PubMed ID: 7083455
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients.
Hande KR; Wedlund PJ; Noone RM; Wilkinson GR; Greco FA; Wolff SN
Cancer Res; 1984 Jan; 44(1):379-82. PubMed ID: 6690051
[TBL] [Abstract][Full Text] [Related]
9. Limited sampling models for reliable estimation of etoposide area under the curve.
Holz JB; Köppler H; Schmidt L; Fritsch HW; Pflüger KH; Jungclas H
Eur J Cancer; 1995 Oct; 31A(11):1794-8. PubMed ID: 8541103
[TBL] [Abstract][Full Text] [Related]
10. Predicting etoposide toxicity: relationship to organ function and protein binding.
Joel SP; Shah R; Clark PI; Slevin ML
J Clin Oncol; 1996 Jan; 14(1):257-67. PubMed ID: 8558207
[TBL] [Abstract][Full Text] [Related]
11. Plasma etoposide catechol increases in pediatric patients undergoing multiple-day chemotherapy with etoposide.
Zheng N; Felix CA; Pang S; Boston R; Moate P; Scavuzzo J; Blair IA
Clin Cancer Res; 2004 May; 10(9):2977-85. PubMed ID: 15131033
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide.
Stewart DJ; Nundy D; Maroun JA; Tetreault L; Prior J
Cancer Treat Rep; 1985 Mar; 69(3):269-73. PubMed ID: 3884152
[TBL] [Abstract][Full Text] [Related]
13. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
You B; Tranchand B; Girard P; Falandry C; Ribba B; Chabaud S; Souquet PJ; Court-Fortune I; Trillet-Lenoir V; Fournel C; Tod M; Freyer G
Lung Cancer; 2008 Nov; 62(2):261-72. PubMed ID: 18442869
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic optimisation of treatment with oral etoposide.
Toffoli G; Corona G; Basso B; Boiocchi M
Clin Pharmacokinet; 2004; 43(7):441-66. PubMed ID: 15139794
[TBL] [Abstract][Full Text] [Related]
15. A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients.
Tranchand B; Amsellem C; Chatelut E; Freyer G; Iliadis A; Ligneau B; Trillet-Lenoir V; Canal P; Lochon I; Ardiet CJ
Cancer Chemother Pharmacol; 1999; 43(4):316-22. PubMed ID: 10071983
[TBL] [Abstract][Full Text] [Related]
16. Etoposide pharmacokinetics in patients with normal and abnormal organ function.
Arbuck SG; Douglass HO; Crom WR; Goodwin P; Silk Y; Cooper C; Evans WE
J Clin Oncol; 1986 Nov; 4(11):1690-5. PubMed ID: 3772420
[TBL] [Abstract][Full Text] [Related]
17. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation.
Lowis SP; Pearson AD; Newell DR; Cole M
Cancer Res; 1993 Oct; 53(20):4881-9. PubMed ID: 8402676
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.
Kaul S; Igwemezie LN; Stewart DJ; Fields SZ; Kosty M; Levithan N; Bukowski R; Gandara D; Goss G; O'Dwyer P
J Clin Oncol; 1995 Nov; 13(11):2835-41. PubMed ID: 7595746
[TBL] [Abstract][Full Text] [Related]
19. Drug monitoring of etoposide (VP16-213). I. A combined method of liquid chromatography and mass spectrometry.
Danigel H; Pflüger KH; Jungclas H; Schmidt L; Dellbrügge J
Cancer Chemother Pharmacol; 1985; 15(2):121-4. PubMed ID: 2990749
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of etoposide in gestochoriocarcinoma.
D'Incalci M; Sessa C; Rossi C; Roviaro G; Mangioni C
Cancer Treat Rep; 1985 Jan; 69(1):69-72. PubMed ID: 2981622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
